Market News & Trends
Viridian Therapeutics Announces FDA Clearance of Investigational New Drug Application to Initiate Clinical Development of VRDN-002, a Next-Generation IGF-1R Antibody for the Treatment of Thyroid Eye Disease
Viridian Therapeutics, Inc. recently announced the US FDA clearance of its investigational new drug (IND) application of VRDN-002. The Company’s next generation IGF-1R antibody, VRDN-002,…
Celsion Corporation Advances Proof of Concept to Non-human Primate Challenge Study Against SARS-CoV-2 With In-Process Vaccine Candidate
Celsion Corporation recently announced it has engaged BIOQUAL, Inc., a preclinical testing contract research organization, to conduct a non-human primate (NHP) challenge study with Celsion’s DNA-based approach for….
Veru Announces FDA Grant of Fast Track Designation for Sabizabulin for the Treatment of Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome
Veru Inc. recently announced the US FDA has granted Fast Track designation to the Phase 3 registration program for the investigation of sabizabulin, a novel,…
Biogen Reaches Agreement With Samsung Biologics to Sell Equity Stake in Their Biosimilar Joint Venture for up to $2.3 Billion
Biogen Inc. recently announced it has entered into an agreement whereby Samsung Biologics will acquire Biogen’s equity stake in the Samsung Bioepis joint venture for an aggregate consideration of up to….
Owen Mumford Announces on Market Release of UniSafe 1-mL Safety Device for Pre-filled Syringes Featuring Industry-First Spring-less Mechanism
Owen Mumford Pharmaceutical Services recently announced its UniSafe 1-mL safety device for pre-filled syringes has been approved as a combination product in Asia. In Europe,…
Maravai LifeSciences Acquires MyChem, a Leader in Proprietary Ultra-Pure Nucleotides
Maravai LifeSciences, Inc. recently announced it has acquired MyChem, LLC for $240 million in cash at closing with the potential for additional contingent cash consideration based on achievement of….
Enable Injections Announces $215-Million Financing
Enable Injections, Inc. recently announced $215 million in Series C financing. Magnetar Capital (Magnetar) led the financing along with new institutional investments from….
Recipharm Secures Vaccine Manufacturing Deal
Global contract development and manufacturing organization (CDMO), Recipharm, has recently inked a deal with a top 10 big pharma company to support vaccine manufacturing from its….
Kymanox Expands Management Team With New Head of Digital Quality, Steve Lupo
Kymanox Corporation, a professional services company exclusively serving the Life Science industry, recently announced the addition of Steve Lupo as the Head of CGxP Digital…
atai Life Sciences Launches Invyxis to Accelerate Discovery of Next-Generation Mental Health Treatments
atai Life Sciences N.V. recently launched Invyxis, a new, wholly owned platform company committed to developing new chemical entities (NCEs) and to further pioneering next-generation…
Vivos Therapeutics Files for US Patent on Proprietary New Clinical Protocols After Seeing Further Significant Improvement in Reduction of Key Sleep Apnea Metric
Vivos Therapeutics, Inc. recently announced the filing of a US patent application related to certain new and enhanced clinical methods and protocols developed within Vivos’…
Yamo Pharmaceuticals Announces Enrollment of First Patient in Phase 2 Study of L1-79 in Autism Spectrum Disorder
Yamo Pharmaceuticals recently announced the first patient has been treated in a Phase 2 study of L1-79 in adolescents and young adults with ASD at…
Cocrystal Pharma Selects Two Lead Antiviral Drug Candidates for its COVID-19 Oral Drug Program
Cocrystal Pharma, Inc. has selected two investigational novel antiviral drug candidates for further development as oral treatments for SARS-CoV-2, the virus that causes COVID-19…..
TFF Pharmaceuticals Completes Enrollment in Phase 1 Study Evaluating Inhaled Formulation of Niclosamide to Treat COVID-19
TFF Pharmaceuticals, Inc. recently announced it has completed enrollment of 40 healthy subjects in its Phase 1 clinical trial (CT.gov identifier NCT05168644) of a dry…
PDS Biotech Announces Preclinical Data for PDS0202 Universal Influenza Vaccine
PDS Biotechnology Corporation recently announced preclinical data for its universal flu vaccine, which was shown to be effective against….
Provectus Biopharmaceuticals Provides Update on Research into PV-10 Immunotherapy as an Immune Adjuvant for Making Vaccines Work Better
Provectus recently provided an update on research of its investigational immunotherapy PV-10 (rose bengal sodium, a halogenated xanthene small molecule) as an immune adjuvant in…
Allergy Therapeutics Announces FDA Clearance of IND Application for Novel Peanut Allergy Vaccine Candidate
Allergy Therapeutics recently announced the US FDA has cleared the Group’s Investigational New Drug application (IND) for its novel virus-like particle (VLP)-based peanut allergy vaccine…
Evaxion Biotech Announces Publication of Clinical Data of EVX-01 Heading Into Phase 2b in Collaboration With Merck
Evaxion Biotech A/S recently announced the publication of a paper on personalized therapy with EVX-01 in patients with metastatic melanoma in the open access, peer-reviewed….
Cyclerion Therapeutics Announces Initiation of Patient Dosing in CY6463 Phase 2a Study in Alzheimer’s Disease With Vascular Pathology
Cyclerion Therapeutics, Inc. recently announced patient dosing has begun in its Phase 2a study in Alzheimer’s Disease with Vascular Pathology (ADv). “The need for effective…
Hepion Pharmaceuticals’ Rencofilstat, in Combination With an Immune Checkpoint Inhibitor, Demonstrates Synergistic Anti-Tumor Activity in a Nonclinical Liver Cancer Study
Hepion Pharmaceuticals, Inc. recently announced the results of a nonclinical research study showing that its clinical phase drug candidate, rencofilstat (CRV431), synergistically decreased liver tumor….